

MedAdvisor Limited ACN 145 327 617 Level 2, 971 Burke Road Camberwell Vic 3124 mymedadvisor.com/investors

## **MARKET RELEASE**

## Resignation of joint company secretary

**Melbourne, Australia, 1 June, 2021 -** Medtech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) (ASX: MDR) announces that, as previously foreshadowed in 2020, Mr Carlo Campiciano has resigned as joint company secretary, effective today. Ms Naomi Lawrie will continue as sole company secretary.

For the purpose of ASX Listing Rule 12.6, the Company confirms that Ms Lawrie will be responsible for communication between the Company and the ASX.

"The Board thanks Carlo for his substantial contribution to the Company and wishes him well in his retirement," said MedAdvisor CEO Robert Read.

## **About MedAdvisor**

MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.8 million patients through more than 65% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors

- ENDS -

This document has been authorised for release by Robert Read, MedAdvisor CEO.

## For more information:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Alex Beashel
Corporate Communications
<a href="mailto:ab@alexbeashel.com">ab@alexbeashel.com</a>
+61 466 308 667